Go to PegaPoll
PEGAPOLL · NEWS

FDA rejects Capricor Therapeutics cell therapy for Duchenne muscular dystrophy

STAT News · 2026-11-20
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.

The Food and Drug Administration rejected Capricor Therapeutics' cell therapy, deramiocel, intended for patients with Duchenne muscular dystrophy. Regulators blocked the treatment after two randomized clinical trials failed to demonstrate that the therapy could prevent heart failure or preserve muscle function in teenage and young adult patients who can no longer walk.

Continue in the app — vote & join in ➔
Source: STAT News · via ahirlevel.hu

Related news